Clinical Trial Update: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) [Phase 2]

View source ↗

Summary

Clinical trial update indicates completion of the Phase 2 JACKPOT27 study of AZD4205 for relapsed or refractory peripheral T-cell lymphoma conducted by Dizal Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZD4205

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: COMPLETED